S9: Prolyl oligopeptidase | Enzymes | IUPHAR/BPS Guide to PHARMACOLOGY

S9: Prolyl oligopeptidase C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

GtoImmuPdb view: OFF

Enzymes

acylaminoacyl-peptide hydrolase Show summary »« Hide summary More detailed page

dipeptidyl peptidase 4 C Show summary »« Hide summary More detailed page

Target Id

1612

Nomenclature

dipeptidyl peptidase 4

Previous and unofficial names

Genes

DPP4 (Hs), Dpp4 (Mm), Dpp4 (Rn)

Ensembl ID

ENSG00000197635 (Hs), ENSMUSG00000035000 (Mm), ENSRNOG00000030763 (Rn)

UniProtKB AC

P27487 (Hs), P28843 (Mm), P14740 (Rn)

EC number

3.4.14.5

Endogenous substrates

glucagon-like peptide 1

Inhibitors

saxagliptin pK_i 9.2 [3]

linagliptin pK_i 9.0 [2]

vildagliptin pK_i 7.8 [3]

sitagliptin pIC₅₀ 8.1 [1]

dipeptidyl peptidase 8 Show summary »« Hide summary More detailed page

Target Id

2356

Nomenclature

dipeptidyl peptidase 8

Previous and unofficial names

Genes

DPP8 (Hs), Dpp8 (Mm), Dpp8 (Rn)

Ensembl ID

ENSG00000074603 (Hs), ENSMUSG00000032393 (Mm)

UniProtKB AC

Q6V1X1 (Hs), Q80YA7 (Mm)

EC number

3.4.14.5

dipeptidyl peptidase 9 Show summary »« Hide summary More detailed page

fibroblast activation protein alpha Show summary »« Hide summary More detailed page

prolyl endopeptidase Show summary »« Hide summary More detailed page

prolyl endopeptidase-like Show summary »« Hide summary More detailed page

References

Show »« Hide

1. Davis JA, Singh S, Sethi S, Roy S, Mittra S, Rayasam G, Bansal V, Sattigeri J, Ray A. (2010) Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals. Indian J Pharmacol, 42 (4): 229-33. [PMID:20927248]

2. Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P et al.. (2007) 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 50 (26): 6450-3. [PMID:18052023]

3. Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. (2009) Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets, 10 (1): 71-87. [PMID:19149538]

How to cite this family page

Database page citation:

S9: Prolyl oligopeptidase. Accessed on 12/07/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=758.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol. 172: 6024-6109.